You are here: Industry Insights > Dyadic

News List

Dyadic and Rubic to develop Covid-19 vaccines for African markets pharmaceutical-technology
July 28, 2021
Dyadic International has entered a Covid-19 vaccine technology transfer and licensing agreement with South Africa-based company, Rubic Consortium, to discover, develop, analyse and produce cost-efficient vaccines for supply mainly to the African markets.
Dyadic Collaborates with Syngene to Develop Covid-19 Vaccine Candidate contractpharma
May 27, 2021
Dyadic International Inc. a global biotechnology company, has entered into a collaboration with Syngene International Limited, an integrated research, development, and manufacturing services company, to develop a COVID-19 vaccine candidate that can ...
Dyadic and Medytox to co-develop Covid-19 variant fighting vaccines pharmaceutical-business-review
March 26, 2021
US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines.
Dyadic and TurtleTree Scientific enter strategic partnership prnasia
February 03, 2021
Dyadic International, Inc. announced a fully funded collaboration with TurtleTree Scientific to develop a number of recombinant proteins growth factors which can be manufactured at high yields and low cost in bioreactors.
Dyadic to Develop Cell Lines for COVID-19 Vaccine Candidates contractpharma
June 11, 2020
Selected by the Frederick National Laboratory to engineer proprietary C1 cell lines.
Dyadic, Serum Institute of India collaborate for antibodies and vaccines biospectrumasia
May 15, 2019
Under the terms of this collaboration, Serum anticipates applying Dyadic's C1 technology to express up to twelve proteins - 8 MABs and 4 rVaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from